DHA Summary Suspension: What Military Healthcare Providers Must Know

| | | | |

DHA Summary Suspension: What Military Healthcare Providers Must Know

One notice. One suspension. And a military healthcare provider’s career can shift permanently before they fully understand what is happening. The DHA summary suspension process is among the most consequential — and least understood — administrative proceedings in the Military Health System. What you don’t know about it will cost you.

This chapter breaks it down section by section: what a summary suspension is, what triggers it, what it does to your clinical practice, what rights you have, and how it connects to your state medical license. Each section is short, direct, and grounded in DHA policy and federal reporting requirements.

Chapter 1.0 — Summary Suspension Overview

A summary suspension is an immediate administrative action initiated by the Privileging Authority that temporarily suspends all or part of a provider’s clinical privileges or scope of practice. It is typically imposed when a provider’s continued practice is believed to pose a risk to patient safety or the integrity of healthcare services within a Military Treatment Facility (MTF).

Under DHA-PM 6025.13, the DHA’s Clinical Quality Management policy, summary suspension authority exists to protect patient safety, operational readiness, and the integrity of military healthcare. The action is protective, not punitive — but that distinction does little to soften its immediate impact.

Immediate action may be imposed in situations involving allegations of unsafe clinical practice, impairment concerns, professional misconduct, documentation irregularities affecting patient care, or significant deviation from accepted standards of care. DHA policy does not require final proof of wrongdoing — the threshold is whether immediate restriction is necessary pending formal investigation.

Key Policy Point

The provider must be formally notified in writing, and proof of delivery is required. If the provider refuses to sign, a witness documents the refusal with their name, signature, and date.

A summary suspension remains in effect while the Clinical Adverse Action (CAA) process is ongoing. For privileged providers, if the suspension extends beyond 30 days, it becomes a reportable event to the National Practitioner Data Bank (NPDB), as well as to applicable state licensing boards and relevant certifying or regulatory agencies. This single threshold is one of the most consequential timelines in the entire process.

Under DHA procedures, the formal notice of summary suspension must clearly state the basis for the suspension, specify whether all or only certain privileges are suspended, inform the provider that a Clinical Adverse Action has been initiated, and outline the provider’s rights and procedural safeguards. In most cases, it also advises that a Quality Assurance (QA) Investigation has begun.

Providers subject to summary suspension should carefully review the written notice, strictly adhere to all response deadlines, preserve all documentation and communications, and avoid informal or undocumented explanations. Seek experienced legal and professional guidance immediately. Early, informed action can significantly affect whether privileges are restored, modified, or formally restricted.

1.1 — Grounds for Summary Suspension

The DHA is a joint Combat Support Agency that manages and directs MTFs for the Army, Navy, and Air Force. Pursuant to DHA-PM 6025.13 governing Clinical Quality Management and Clinical Adverse Actions, the Privileging Authority holds the power to immediately restrict or suspend clinical privileges when necessary to safeguard patients — without waiting for a final determination of wrongdoing.

A summary suspension may be imposed when there is reasonable belief that a provider’s continued practice poses an imminent threat to patient safety, staff welfare, operational readiness, or the integrity of clinical services. Commonly cited grounds include:

  • Conduct detrimental to mission effectiveness — actions that undermine operational readiness
  • Suspected misconduct — including behavioral or ethical violations
  • Professional impairment — substance use, behavioral health concerns, or fitness-for-duty issues
  • Clinical incompetence — pattern of errors or demonstrated skill deficiency
  • Gross deviation from standards of care — single or repeated serious departures

Critical Distinction

DHA policy does not require final proof of wrongdoing before imposing summary suspension. The threshold is whether immediate restriction is necessary pending formal investigation. The bar is low; the consequences are not.

Unlike a state license suspension — which affects the provider’s legal authority to practice within a state — a DHA summary suspension affects privileges within the Military Health System only. However, the practical consequences may be equally significant, particularly once NPDB reporting thresholds are crossed and state licensing boards become involved.

Sources & References

  • Defense Health Agency. DHA Procedures Manual 6025.13, Volume 3 — Clinical Quality Management, Healthcare Risk Management. health.mil (PDF)
  • Department of Defense. DoDI 6025.13 — Medical Quality Assurance and Clinical Quality Management in the Military Health System. omb.report
  • National Practitioner Data Bank (NPDB). Reporting Clinical Privileges Actions — NPDB Guidebook. npdb.hrsa.gov
  • Ward & Smith, P.A. Understanding the Pitfalls of a Defense Health Agency (DHA) Investigation. wardandsmith.com